Quiz
Article
Author(s):
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.
This week, we’ll focus on recent developments and updates in psoriatic arthritis from the ongoing European Alliance of Associations for Rheumatology 2025 Congress.
Do you have a set of quiz questions to share? Contact editor Emma Andrus at eandrus@mjhlifesciences.com to contribute!
Which dual cytokine pathway does bimekizumab (Bimzelx) target in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA)?
In the BE OPTIMAL, BE COMPLETE, and BE VITAL trials, what percentage of patients with active PsA achieved elimination of swollen joints (SJC=0) at 3 years with bimekizumab, regardless of prior treatment exposure?
Which biologic is currently the only IL-23 inhibitor shown in phase 3 trials to significantly inhibit progression of joint structural damage in PsA?
References
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.